phenylephrine hydrochloride; promethazine hydrochloride
Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
PHENERGAN VC is a combination oral syrup containing phenylephrine hydrochloride (a decongestant) and promethazine hydrochloride (an antihistamine with anticholinergic properties). It is used to treat symptoms of allergic reactions, colds, and upper respiratory conditions. The formulation addresses nasal congestion and allergic symptoms through dual-mechanism symptomatic relief.
LOE approaching signals potential team downsizing and resource reallocation away from legacy maintenance toward next-generation pipeline programs.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
PHENERGAN VC offers limited career growth opportunity due to its mature, LOE-approaching lifecycle and declining market relevance. Roles available are primarily in defensive commercial and operations functions focused on margin protection and efficient portfolio management rather than innovation.
Worked on PHENERGAN VC at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo